Peptides DB
Research-centric peptide and protocol reference hub

SS-31 record · updated 18h ago

Healing & recoveryNeuro & moodGrade A · human clinicalResearch use only
All 38 studiesJump to the evidenceCompare
What is SS-31 used for?

SS-31, also known as Elamipretide, is a peptide that has garnered attention for its potential role in mitochondrial protection and its implications in various health conditions, particularly those involving oxidative stress and mitochondrial dysfunction.

How it works: Cardiolipin binding to stabilize mitochondrial membrane

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where SS-31 sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 24 registered trials. It describes the research record, not a recommendation.

Identity
NameSS-31
Chain length—
Molecular weight639.8 Da
FormulaC32H49N9O5
Structure typeNot established
ClassMetabolic
Research levelPreclinical
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 11764719. No verified residue count for this compound.

Pharmacology
MechanismCardiolipin binding to stabilize mitochondrial membrane
RouteSubcutaneous injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.70
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 19, 2026. How this works →
Research stats
Total studies38
Human / animal / cellular23 / 2 / 4
Highest trial phasePreclinical
Years covered2010–2026
Latest study1mo ago
Publication history
20102026
Research funding
29,134 NIH projects · $24.3M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

38 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Structural and functional characterisation of the dextran utilisome from <i>Bacteroides thetaiotaomicron</i>.
FindingNot reported in abstract.
In vitro2026Full text read0.80
4-oxo-quinoline based fluorescent chemosensors for on-site detection of G-type nerve agent mimic DCP via spectroscopic and theoretical insights.
FindingLimit of detection for DCP: 0.14 μM for 6DEQA.
In vitro2026Full text read0.80
Effectiveness of virtual reality-based rehabilitation on quality of life and upper extremity functions among stroke survivors: A systematic review and meta-analysis.
FindingSMD = -0.09, 95% CI -0.30 to 0.11, p = .36; low certainty for QoL.
review2026Full text read0.80
Kidney failure risk equation and early renal risk in adults with sickle cell disease: comparison with KDIGO classification using measured GFR.
Finding35.7% of participants had moderate-to-high KDIGO renal risk.
Human2026Full text read0.80
Association of basal metabolic rate with mortality among cancer survivors: a cohort study emphasizing heterogeneity by gender and age.
FindingHigher BMR was associated with reduced prevalence of all-cause mortality in older survivors aged ≥60 years.
Human2026Full text read0.80
Assessing health beliefs and patient delay among breast cancer patients in West Sumatra, Indonesia.
FindingCronbach's α: 0.809-0.871 for the final tool.
Human2026Full text read0.80
Diagnostic performance of Xpert MTB/RIF Ultra assay for tuberculosis in stool specimens among adult presumptive TB patients in a generalized HIV epidemic setting
FindingSensitivity of Xpert-Ultra assay in stool specimen was 90.32% (95% CI, 74.25% to 97.96%)
Human2026Full text read0.80
Mirusha virus: A novel sand fly-borne phlebovirus with evidence of neutralizing antibodies in humans and dogs in Kosovo.
FindingNeutralizing antibodies detected in dogs (2.0%) and humans (0.8%) in Kosovo.
Human2026Full text read0.80
The clinical significance of exploring concurrent nephropathy in patients with primary renal malignancies.
FindingAll-cause mortality 19.4% vs. 0%, p=0.007.
Human2026Full text read0.80
Statistical analysis plan for the ‘Pharyngeal electrical stimulation for acute stroke dysphagia trial’ (PhEAST) (ISRCTN98886991)
FindingNot reported in abstract.
review2026Partial text0.50
Use of nicotine replacement therapy to reduce children’s exposure to second-hand smoke in the home: Findings of a pilot randomised controlled trial conducted in Scotland
FindingMedian PM 2.5 concentrations reduced in the intervention group by -36μg/m 3.
Human2026Full text read0.80
Cardiovascular and autonomic responses to transcutaneous spinal cord stimulation combined with activity-based therapy after chronic spinal cord injury: An exploratory study from the MACHINE trial
FindingNot reported in abstract.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching SS-31 will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much SS-31 is discussed should be drawn from it.

Articles mentioning SS-31